FOUR DRUG REGIMEN VS THREE DRUG REGIMEN IN HIV INFECTED SUBJECTS

HIV 感染者的四种药物治疗方案与三种药物治疗方案

• 批准号: 6297258
• 负责人: Joseph J Eron
• 金额: $ 0.02万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297258
• 关键词: 2'3' dideoxynucleoside; AIDS therapy; HIV infections; antiAIDS agent; clinical research; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; lamivudine; protease inhibitor; reverse transcriptase inhibitors; zidovudine

The purpose of the study is to examine whether or not the quadruple regimen of 141W94 1200 mg bid, abacavir 300 mg bid, and Combivir (TM) bid is superior in efficacy to the triple regimen of Nelfinavir 750 mg tid and Combivir (TM) bid in antiretroviral-naive, HIV-infected subjects with baseline HIV RNA > or = 5000 copies/mL and baseline CD4 > or = 50 cells/mme, in the presence of comparable safety and tolerability profiles for the treatment arms.

该研究的目的是检查141W94 1200 mg BID，ABACAVIR 300 mg BID和COMBIVIR（TM）竞标的四个方案是否优于Nelfinavir 750 mg TID和Combivir（TM）的抗抗反感（TM）抗逆转录病毒率r的三倍方案5000副本/mL和基线CD4> OR = 50个单元/mme，在存在可比的安全性和可耐受性的情况下。